Down Syndrome Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Down Syndrome is witnessing steady growth driven by the rising Disease Prevalence and Diagnosis Rates, Increasing Demand for Effective Supportive and Symptomatic Therapies, and Growing Preference for Personalized and Non-pharmacological Treatment Approaches. Additionally, the launch of emerging therapies such as AEF0217 (Aelis Farma), ACI-24.060 (AC Immune/Takeda), CTH120 (Connecta Therapeutics), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Down Syndrome Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Down Syndrome, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Down Syndrome Market
• The market size for Down Syndrome in the leading markets is expected to grow significantly by 2036.
• The United States accounted for the highest Down Syndrome treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• DelveInsight's analysis indicates that the prevalence of Down Syndrome across the 7MM is significant, highlighting the disorder's presence across different populations globally.
• Data indicate that approximately 730K diagnosed prevalent cases of Down Syndrome were reported across the 7MM in 2025, while around 315 thousand cases were reported in the United States alone.
• Leading Down Syndrome companies, such as Aelis Farma, AC Immune, Takeda, Connecta Therapeutics, and others, are developing new Down Syndrome treatment drugs that can be available in the Down Syndrome market in the coming years.
• The promising Down Syndrome therapies in clinical trials include AEF0217, ACI-24.060, CTH120, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Down Syndrome Market
• Rising Disease Prevalence and Diagnosis Rates: Increasing awareness of genetic disorders, improved prenatal and diagnostic screening tools, and expanding healthcare access are helping identify more patients with Down Syndrome. Earlier diagnosis and better recognition are contributing to treatment demand.
• Increasing Demand for Effective Pharmacological Therapies: The pharmacological management of Down Syndrome primarily involves medications addressing associated neurological and cognitive impairments. Therapies such as cholinesterase inhibitors and other supportive treatments are being explored to improve cognitive function and overall outcomes.
• Growing Preference for Personalized and Non-drug Therapies: Therapies such as Cognitive Behavioral interventions, speech therapy, occupational therapy, and physical therapy are increasingly utilized. Early intervention programs and supportive care approaches are also gaining traction.

Down Syndrome Competitive Landscape
• Several Down Syndrome drugs in development include AEF0217 (Aelis Farma), ACI-24.060 (AC Immune/Takeda), CTH120 (Connecta Therapeutics), and others.
• These candidates target diverse mechanisms anti-amyloid approaches, and neuroplasticity enhancement, aiming to improve cognitive symptoms in Down Syndrome with better efficacy and fewer side effects than current treatments.

Discover more about therapies set to grab major Down Syndrome market share at https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Down Syndrome Market
• In January 2026, Aelis Farma reported updates on AEF0217 development program for Down Syndrome, highlighting its progress in clinical evaluation.
• In March 2025, Connecta Therapeutics reported the initiation and progress of clinical evaluation of CTH120, supporting its potential role in neurodevelopmental disorders including Down Syndrome.

What is Down Syndrome?
Down Syndrome, also known as trisomy 21, causes developmental delays, intellectual disability, and characteristic physical features that significantly impact daily functioning. These manifestations go beyond typical developmental variations, leading to cognitive impairment and associated health conditions. Symptoms range from mild to severe, affecting multiple organ systems and requiring lifelong management.

Down Syndrome Epidemiology Segmentation
The Down Syndrome epidemiology section provides insights into the historical and current Down Syndrome patient pool and forecasted trends for the leading markets. The Down Syndrome market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
• Total Diagnosed Prevalent Cases of Down Syndrome
• Type-specific Diagnosed Prevalent Cases of Down Syndrome
• Severity-specific Diagnosed Prevalent Cases of Down Syndrome
• Age-specific Diagnosed Prevalent Cases of Down Syndrome

Scope of the Down Syndrome Market Report
• Therapeutic Assessment: Down Syndrome current marketed and emerging therapies
• Down Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging
• Down Syndrome Drugs and Market Outlook
• Key Companies: Aelis Farma, AC Immune, Takeda, Connecta Therapeutics, and others
• Key Therapies: AEF0217, ACI-24.060, CTH120, and others
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Down Syndrome Market Access and Reimbursement

To know more about Down Syndrome companies working in the treatment market, visit https://www.delveinsight.com/sample-request/down-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Down Syndrome Market Report Introduction
2. Executive Summary for Down Syndrome
3. SWOT Analysis of Down Syndrome
4. Down Syndrome Patient Share (%) Overview at a Glance
5. Down Syndrome Market Overview at a Glance
6. Down Syndrome Background and Overview
7. Down Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Down Syndrome
9. Down Syndrome Current Treatment and Medical Practices
10. Down Syndrome Unmet Needs
11. Down Syndrome Emerging Therapies
12. Down Syndrome Market Outlook
13. Country-Wise Down Syndrome Market Analysis (2022-2036)
14. Down Syndrome Market Access and Reimbursement of Therapies
15. Down Syndrome Market Drivers
16. Down Syndrome Market Barriers
17. Down Syndrome Appendix
18. Down Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About Delveinsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.